U.S. markets closed
S&P Futures
4,109.50-13.50(-0.33%)Dow Futures
33,894.00-102.00(-0.30%)Nasdaq Futures
13,169.50-42.50(-0.32%)
La Jolla Pharmaceutical Company (LJPC)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.6600-0.0900 (-2.40%)
At close: 4:00PM EDT
3.6600 0.00 (0.00%)
After hours: 12:00AM EDT
After hours: 12:00AM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 3.7500 |
| Open | 3.7700 |
| Bid | 3.6100 x 800 |
| Ask | 3.7000 x 800 |
| Day's Range | 3.6200 - 3.8400 |
| 52 Week Range | 3.3500 - 7.8500 |
| Volume | 132,851 |
| Avg. Volume | 233,760 |
| Market Cap | 102.932M |
| Beta (5Y Monthly) | 2.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5990 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.17 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Zacks
Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
- Zacks
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress.
© 2021 Verizon Media. All rights reserved.
